Literature DB >> 22143798

Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses.

Matthew R Sandbulte1, Kim B Westgeest, Jin Gao, Xiyan Xu, Alexander I Klimov, Colin A Russell, David F Burke, Derek J Smith, Ron A M Fouchier, Maryna C Eichelberger.   

Abstract

Seasonal epidemics caused by influenza virus are driven by antigenic changes (drift) in viral surface glycoproteins that allow evasion from preexisting humoral immunity. Antigenic drift is a feature of not only the hemagglutinin (HA), but also of neuraminidase (NA). We have evaluated the antigenic evolution of each protein in H1N1 and H3N2 viruses used in vaccine formulations during the last 15 y by analysis of HA and NA inhibition titers and antigenic cartography. As previously shown for HA, genetic changes in NA did not always lead to an antigenic change. The noncontinuous pattern of NA drift did not correspond closely with HA drift in either subtype. Although NA drift was demonstrated using ferret sera, we show that these changes also impact recognition by NA-inhibiting antibodies in human sera. Remarkably, a single point mutation in the NA of A/Brisbane/59/2007 was primarily responsible for the lack of inhibition by polyclonal antibodies specific for earlier strains. These data underscore the importance of NA inhibition testing to define antigenic drift when there are sequence changes in NA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22143798      PMCID: PMC3251064          DOI: 10.1073/pnas.1113801108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.

Authors:  J C de Jong; W E Beyer; A M Palache; G F Rimmelzwaan; A D Osterhaus
Journal:  J Med Virol       Date:  2000-05       Impact factor: 2.327

2.  Effect of neuraminidase antibody on Hong Kong influenza.

Authors:  A S Monto; A P Kendal
Journal:  Lancet       Date:  1973-03-24       Impact factor: 79.321

3.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

4.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.

Authors:  C B Bridges; W W Thompson; M I Meltzer; G R Reeve; W J Talamonti; N J Cox; H A Lilac; H Hall; A Klimov; K Fukuda
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

5.  Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice.

Authors:  J L Schulman; M Khakpour; E D Kilbourne
Journal:  J Virol       Date:  1968-08       Impact factor: 5.103

6.  Antiviral activity of antiserum specific for an influenza virus neuraminidase.

Authors:  E D Kilbourne; W G Laver; J L Schulman; R G Webster
Journal:  J Virol       Date:  1968-04       Impact factor: 5.103

7.  Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus.

Authors:  J L Schulman; E D Kilbourne
Journal:  Proc Natl Acad Sci U S A       Date:  1969-06       Impact factor: 11.205

8.  Mapping the antigenic and genetic evolution of influenza virus.

Authors:  Derek J Smith; Alan S Lapedes; Jan C de Jong; Theo M Bestebroer; Guus F Rimmelzwaan; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  Science       Date:  2004-06-24       Impact factor: 47.728

9.  Immunological relationships between the neuraminidases of human and animal influenza viruses.

Authors:  G C Schild; R W Newman
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

10.  The role of antineuraminidase antibody in immunity to influenza virus infection.

Authors:  J L Schulman
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

View more
  96 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.

Authors:  Judith D Easterbrook; Louis M Schwartzman; Jin Gao; John C Kash; David M Morens; Laura Couzens; Hongquan Wan; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Virology       Date:  2012-06-22       Impact factor: 3.616

Review 3.  Immune history and influenza virus susceptibility.

Authors:  Sarah Cobey; Scott E Hensley
Journal:  Curr Opin Virol       Date:  2017-01-12       Impact factor: 7.090

4.  Recombinant influenza A H3N2 viruses with mutations of HA transmembrane cysteines exhibited altered virological characteristics.

Authors:  Jianqiang Zhou; Shun Xu; Jun Ma; Wen Lei; Kang Liu; Qiliang Liu; Yida Ren; Chunyi Xue; Yongchang Cao
Journal:  Virus Genes       Date:  2013-11-23       Impact factor: 2.332

Review 5.  The evolution of seasonal influenza viruses.

Authors:  Velislava N Petrova; Colin A Russell
Journal:  Nat Rev Microbiol       Date:  2017-10-30       Impact factor: 60.633

Review 6.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

7.  Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.

Authors:  Diana D Y Wong; Ka-Tim Choy; Renee W Y Chan; Sin Fun Sia; Hsin-Ping Chiu; Peter P H Cheung; Michael C W Chan; J S Malik Peiris; Hui-Ling Yen
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

8.  How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example.

Authors:  Andreas Handel; Victoria Akin; Sergei S Pilyugin; Veronika Zarnitsyna; Rustom Antia
Journal:  J R Soc Interface       Date:  2014-01-15       Impact factor: 4.118

9.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

Review 10.  Targeting the skin for microneedle delivery of influenza vaccine.

Authors:  Dimitrios G Koutsonanos; Richard W Compans; Ioanna Skountzou
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.